NanoViricides, Inc. (NNVC)
NNVCAMEXBiotechnology: Pharmaceutical Preparations
$1.35
+0.0579 (+4.47%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $34.73m
- P/E
- –
- EPS, last 4 quarters
- $-0.4000
- Dividend yield
- –
- Day range
- –
- 52-week range
- $0.8500 to $2.11
- Average volume
- 1.13m
- Previous close
- $1.30
Analysts
1 coveringStrong Buy1 buy, 0 hold, 0 sell
Targets a year out average $6.00, +343.2% from here
Earnings
next estimate $-0.1000Next report Nov 13, 2026
Sep 2025
+44.4%
Dec 2025
+21.4%
Mar 2026
–
Jun 2026
+9.1%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$1.80m | -$2.23m | -$2.03m | -$2.25m |
| Net income | -$1.78m | -$2.22m | -$1.99m | -$2.22m |
News
3 latestThe company
NanoViricides, Inc. (the 'Company') ( www.nanoviricides.com ) is a clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide class of drug candidates and the nanoviricide technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments. The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The Company's business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- AMEX
- Region
- North America
- Website
- nanoviricides.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.